CYDY (CytoDyn) ROC %: -180.18% (As of Feb. 2026)


CYDY CytoDyn Inc CYDY
28 GF Score
Price $0.25
! 1 Warning Sign
View Full Analysis

What is CytoDyn ROC %?

CytoDyn CYDY -0.48% 28 ROC % is -180.18% as of Feb. 2026. GuruFocus rates CYDY with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. CytoDyn's annualized return on capital (ROC %) for the quarter that ended in Feb. 2026 was -180.18%.

As of today (2026-06-26), CytoDyn's WACC % is 11.01%. CytoDyn's ROC % is -95.99% (calculated using TTM income statement data). CytoDyn earns returns that do not match up to its cost of capital. It will destroy value as it grows.


CytoDyn  (OTCPK:CYDY) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CytoDyn's WACC % is 11.01%. CytoDyn's ROC % is -95.99% (calculated using TTM income statement data). CytoDyn earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


CytoDyn ROC % Related Terms


CytoDyn ROC % Historical Data

* Premium members only.

The historical data trend for CytoDyn's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn ROC % Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -193.39 -226.04 -88.12 -54.77 33.07

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.00 -72.57 -71.08 -73.72 -180.18
CYDY
28GF Score
CytoDyn Inc CYDY
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn ROC % Calculation

CytoDyn's annualized Return on Capital (ROC %) for the fiscal year that ended in May. 2025 is calculated as:

ROC % (A: May. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: May. 2024 ) + Invested Capital (A: May. 2025 ))/ count )
=9.661 * ( 1 - 0% )/( (30.489 + 27.933)/ 2 )
=9.661/29.211
=33.07 %

where

CytoDyn's annualized Return on Capital (ROC %) for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-25.212 * ( 1 - 0% )/( (27.637 + 0.34799999999999)/ 2 )
=-25.212/13.9925
=-180.18 %

where

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18.497 - 50.139 - ( 15.655 - max(0, 50.428 - 18.438+15.655))
=0.34799999999999

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -180.18% mean?
CytoDyn (CYDY) has a ROC % of -180.18% as of Feb. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on CytoDyn and its competitors.
Is CytoDyn's ROC % too high?
CytoDyn's current ROC % is -180.18%. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's ROC % compare to ZURA and XFOR?
CytoDyn's ROC % of -180.18% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on CytoDyn and its competitors. CytoDyn's current ROC % is -180.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current ROC % of -180.18%. The current ROC % is -180.18%. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For CytoDyn (CYDY), the current ROC % is -180.18% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges 296:Germany
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for CYDY

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price